Belite Bio, Inc (BLTE): Price and Financial Metrics
BLTE Price/Volume Stats
| Current price | $56.21 | 52-week high | $86.53 |
| Prev. close | $53.04 | 52-week low | $31.00 |
| Day low | $53.40 | Volume | 42,700 |
| Day high | $56.33 | Avg. volume | 45,718 |
| 50-day MA | $67.61 | Dividend yield | N/A |
| 200-day MA | $53.02 | Market Cap | 1.74B |
BLTE Stock Price Chart Interactive Chart >
Belite Bio, Inc (BLTE) Company Bio
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
BLTE Price Returns
| 1-mo | -12.34% |
| 3-mo | -13.50% |
| 6-mo | 16.26% |
| 1-year | 22.20% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -10.92% |
| 2024 | 37.92% |
| 2023 | 51.77% |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
Loading social stream, please wait...